Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
BioPharma Dive7h
BridgeBio oncology spinout to go public in blank-check merger
The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...
precisionmedicineonline8h
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
FiercePharma9h
CHMP again backs Leqembi amid flurry of approval recommendations
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
Maze Therapeutics receives positive ratings following recent IPO
Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...
stocknews4d
3 Pharmaceutical Stocks With Blockbuster Drug Potential
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
BioPharma Dive4d
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
BioSpace4d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
BioWorld7d
Meiragtx filing MAA on visual benefits with gene therapy
A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...